Ak. Saha et al., LIPID ABNORMALITIES IN TISSUES OF THE KKA(Y) MOUSE - EFFECTS OF PIOGLITAZONE ON MALONYL-COA AND DIACYLGLYCEROL, The American journal of physiology, 267(1), 1994, pp. 50000095-50000101
Insulin resistance is present in liver and muscle of subjects with typ
e 2 diabetes and obesity. Recent studies suggest that such insulin res
istance could be related to abnormalities in lipid-mediated signal tra
nsduction; however, the nature of these abnormalities is unclear. To e
xamine this question further, tissue levels of diacylglycerol (DAG), m
alonyl-CoA, and triglyceride (TG) were determined in liver and soleus
muscle of obese insulin-resistant KKA(y) mice and lean C57 BL control
mice. In addition, the effects of treatment with pioglitazone, an anti
diabetic agent that acts by increasing insulin sensitivity in muscle,
liver, and other tissues, were assessed. The KKA(y) mice were hypergly
cemic (407 vs. 138 mg/dl), hypertriglyceridemic (337 vs. 109 mg/dl), h
yperinsulinemic (631 vs. 15 mU/ml), and weighed more (42 vs. 35 g) tha
n the control mice. They also had 1.5- to 2.0-fold higher levels of ma
lonyl-CoA in both liver and muscle, higher DAG (twofold) and TG (1.3-f
old) levels in muscle, and higher TG (threefold), but not DAG, levels
in liver. Treatment of the KKA(y) mice with pioglitazone for 4 days de
creased plasma glucose, TGs, and insulin by similar to 50% and restore
d hepatic and muscle malonyl-CoA levels to control values. In contrast
, pioglitazone increased hepatic and muscle DAG levels two- or threefo
ld. It had no effect on muscle or hepatic TG content, and it slightly
increased hepatic TGs in the control group. The results indicate that
abnormalities in tissue lipids occur in both liver and muscle of the K
KA(y) mouse and that they are differentially altered when insulin sens
itivity is enhanced by treatment with pioglitazone. Improved insulin s
ensitivity correlated most closely with reduction in the content of ma
lonyl-CoA, suggesting a possible link between the cytosolic concentrat
ion of long chain fatty acyl-CoA and insulin action.